Self-supervised 3D deep learning on preoperative contrast-enhanced computed tomography for predicting high pathologic nodal burden in esophageal squamous cell carcinoma: temporal and external multicohort validation - Top-Institutions - MDSpire

Self-supervised 3D deep learning on preoperative contrast-enhanced computed tomography for predicting high pathologic nodal burden in esophageal squamous cell carcinoma: temporal and external multicohort validation

  • By

  • Qian Li

  • Yongxin Li

  • Jing Bai

  • Jinze Zhang

  • Zhenkai Nie

  • Yanxin Ren

  • Zhantao Li

  • Jin Guo

  • Meng Li

  • Tingting Zhang

  • Xinbo Liu

  • June 11, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The Fourth Hospital of Hebei Medical University
    The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei

    Key Differentiators

    • Oncology

  • #2

    North Estonia Medical Centre (NEMC) Foundation
    North Estonia Medical Centre (NEMC) Foundation

    Tallinn, Harju

    Key Differentiators

    • Oncology

  • #3

    Stanford NSCLC Radiogenomics
    Stanford NSCLC Radiogenomics

    Stanford, California

    Key Differentiators

    • Oncology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #5

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, Massachusetts

    Key Differentiators

    • Oncology

Original Source(s)

Self-supervised 3D deep learning on preoperative contrast-enhanced computed tomography for predicting high pathologic nodal burden in esophageal squamous cell carcinoma: temporal and external multicohort validation

  • by Qian Li, Yongxin Li, Jing Bai, Jinze Zhang, Zhenkai Nie, Yanxin Ren, Zhantao Li, Jin Guo, Meng Li, Tingting Zhang, Xinbo Liu

  • June 11, 2026

Related Content

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

FDA OKs first new sunscreen ingredient in more than 25 years

Ultra-low doses could bring costly cancer treatments to more patients in poorer countries